ARTICLE | Clinical News
LJP 394 tolerance drug targeted to stop production of antibodies to double-stranded DNA: Ended Phase I testing, with no drug-related changes noted, and no adver
January 9, 1995 8:00 AM UTC
La Jolla Pharmaceutical Co. (LJPC), San Diego Product: LJP 394 tolerance drug targeted to stop production of antibodies to double-stranded DNA Indication: Lupus nephritis Status: Ended Phase I testing...